{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:48Z","timestamp":1785886788604,"version":"3.56.0"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The aim of this multicenter retrospective study was to investigate the effectiveness and safety of the available JAK-inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD). Methods: We retrospectively analyzed patients with classified RA and RA-ILD undergoing JAKi in 6 Italian tertiary centers from April 2018 to June 2022. We included patients with at least 6 months of active therapy and one high-resolution chest tomography (HRCT) carried out within 3 months of the start of JAKi treatment. The HRCT was then compared to the most recent one carried out within 3 months before the last available follow-up appointment. We also kept track of the pulmonary function tests. Results: We included 43 patients with RA-ILD and 23 males (53.48%) with a median age (interquartile range, IQR) of 68.87 (61.46\u201375.78) treated with JAKi. The median follow-up was 19.1 months (11.03\u201334.43). The forced vital capacity remained stable in 22\/28 (78.57%) patients, improved in 3\/28 (10.71%) and worsened in 3\/28 (10.71%). The diffusing capacity of lung for carbon monoxide showed a similar trend, remaining stable in 18\/25 (72%) patients, improving in 2\/25 (8%) and worsening in 5\/25 (20%). The HRCT remained stable in 37\/43 (86.05) cases, worsened in 4\/43 (9.30%) and improved in the last 2 (4.65%). Discussion: This study suggests that JAKi therapy might be a safe therapeutic option for patients with RA-ILD in a short-term follow-up.<\/jats:p>","DOI":"10.3390\/jcm12030957","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T02:30:38Z","timestamp":1674786638000},"page":"957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5930","authenticated-orcid":false,"given":"Vincenzo","family":"Venerito","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine\u2014Ionian Area, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Policlinico di Modena, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-1037","authenticated-orcid":false,"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, Universit\u00e0 Degli Studi di Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Florence, 50139 Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlea","family":"Lavista","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine\u2014Ionian Area, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"La Corte","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pedrollo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Scardapane","sequence":"additional","affiliation":[{"name":"Radiology Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Policlinico di Modena, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Senese, Universit\u00e0 Degli Studi di Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Policlinico di Modena, University of Modena and Reggio Emilia, 41124 Modena, Italy"},{"name":"Division of Rheumatology, Azienda USL-IRCCS Reggio Emilia, 42421 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine\u2014Ionian Area, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliera Policlinico di Modena, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/RHU.0000000000001720","article-title":"A machine learning approach for predicting sustained remission in rheumatoid arthritis patients on biologic agents","volume":"28","author":"Venerito","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1744666X.2021.1905524","article-title":"Rheumatoid arthritis related interstitial lung disease","volume":"17","author":"Manfredi","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s10067-018-04406-z","article-title":"A bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis","volume":"38","author":"Venerito","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cassone, G., Manfredi, A., Atzeni, F., Venerito, V., Vacchi, C., Picerno, V., Furini, F., Erre, G.L., Tomietto, P., and Fedele, A.L. (2020). Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010277"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_8","first-page":"705","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflame Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice","volume":"21","author":"Sendo","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the International multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"837133","DOI":"10.3389\/fmed.2022.837133","article-title":"Interstitial lung disease in rheumatoid arthritis: A practical review","volume":"9","author":"Laria","year":"2022","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases","volume":"41","author":"Retamozo","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keh464","article-title":"Update on the British society for rheumatology guidelines for prescribing TNF\u03b1 blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: Data from the NEREA registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6652845","DOI":"10.1155\/2021\/6652845","article-title":"Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis","volume":"2021","author":"Vacchi","year":"2021","journal-title":"Case Rep. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: Post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care. Res."},{"key":"ref_21","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","article-title":"Acute exacerbation of interstitial lung disease associated with rheumatic disease","volume":"18","author":"Luppi","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","article-title":"Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature","volume":"11","author":"Manfredi","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:19Z","timestamp":1760120179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12030957"],"URL":"https:\/\/doi.org\/10.3390\/jcm12030957","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}